In Brief: Pall v. Hemasure
This article was originally published in The Gray Sheet
Executive SummaryPall v. Hemasure: Pall files suit alleging that Hemasure's LeukoNet leukocyte removal device for filtering donated blood infringes upon Pall patents covering "the processing of blood or blood products." LeukoNet was cleared by FDA in June 1995 ("The Gray Sheet" Jan. 9, 1995, In Brief). The suit, filed in the U.S. District Court for the Eastern District of New York, seeks an injunction against Hemasure as well as damages. Hemasure says it does not believe LeukoNet infringes "any valid patent rights." Separately, Hemasure announces that it has entered into a collaborative agreement with the Pacific Northwest Regional Blood Services of the American Red Cross, Portland, Oregon, to study the effectiveness of using LeukoNet technology "to remove tumor cells from peripheral stem cell concentrates which are used in certain cancer therapies"...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.